11 November 2026

ECO Animal Health Group plc

(“ECO” or the “Company”)

Capital Markets Day

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it is hosting a Capital Markets Day (“CMD”) today for institutional investors and analysts from 09:30 GMT in the City of London.

Presentations will be given by David Hallas, Chief Executive Officer; Chris Wilks, Chief Financial Officer; Andrew Buglass, Chief Commercial Officer and other members of ECO’s senior leadership team. Topics that will be covered include:

• Commercial strategy and execution for Aivlosin® and ECOVAXXIN® MS;
• Business development priorities and growth opportunities;

• Updates on ECO’s R&D pipeline, including the Company’s current valuation framework for its portfolio. This includes a risk adjusted sum of the parts enterprise valuation for ECOVAXXIN® MS and the R&D portfolio of c. £100m.  In addition, PRRSvmAb which is at proof-of-concept stage, is described and provides an indicative valuation range of £0 - £100m dependent on a key trial completing in the near term.

The event will also include recorded interviews from external speakers including Eurovo, a leading European egg producer which will share its experience with ECOVAXXIN® MS, and Pr. Didier Betbeder, Chief Executive Officer of Vaxinano. In August 2026, ECO signed an exclusive in-licensing agreement with Vaxinano for a sheep vaccine candidate against toxoplasmosis.

David Hallas, Chief Executive Officer of ECO Animal Health, shared: “We look forward to connecting with investors and analysts to demonstrate ECO’s positive progress to date and highlight how we are driving the next generation of animal health products.

With a resilient core business, a self-funded R&D pipeline that has already yielded a commercialised vaccine and a clear business development strategy, ECO is well placed for our next phase of growth.”

The CMD presentation will be available at ecoanimalhealth.com/investors/reports-presentations following the event. Save as above, no new material disclosures will be made at the event.

-Ends-

Contacts

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group’s website or LinkedIn page for further information.